Plain-English translation of NCT07070323 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new immunotherapy called CD5 CAR T-cell therapy for patients with T-cell blood cancers (like certain types of leukemia) that have come back or stopped responding to standard treatments. The treatment works by taking immune cells from your body or a matched donor, genetically modifying them in a lab to recognize and attack cancer cells, and then giving them back to you. This is an early-stage study to see if this approach is safe and effective.
Many patients with relapsed or treatment-resistant T-cell blood cancers have very limited options and poor survival rates with current standard treatments. This medication represents a potentially new way to harness the immune system to fight these aggressive cancers when other therapies have failed.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will first receive chemotherapy to prepare your body for the new immune cells. Then, depending on which group you are assigned to, your treatment cells will come from your own immune system, from a previous stem cell transplant donor, or from a newly matched donor. After receiving the prepared cells, you will be monitored closely during study visits to watch for side effects and to see how well the treatment is working. The study involves up to 54 patients across multiple medical centers.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China